NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The treatment maintains a 46% complete response at 12 ...
Graphical comparison of bladder augmentation surgery using either ileum (top) or a cell-seeded, biodegradable scaffold (bottom). MSCs and HSPCs represent different types of stem cells found in the ...
Preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus Calmette-Guérin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with HER2 expression: A ...
Association between non-luminal molecular subtypes and complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo and BLASST-01 ...
Cellens, a Boston, MA-based cancer diagnostics startup, has raised a $6.5 million seed round. The company is developing a mechanobiology and AI-driven platform, BioFeel, for non-invasive cancer ...
Relmada Therapeutics, Inc. announced the presentation of an abstract at the American Urology Association (AUA2025) conference in Las Vegas, highlighting a study on NDV-01, an investigational therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results